<DOC>
	<DOCNO>NCT02001623</DOCNO>
	<brief_summary>The purpose trial establish tolerability HuMax-TF-ADC mixed population patient specify solid tumor</brief_summary>
	<brief_title>Tisotumab Vedotin ( HuMax®-TF-ADC ) Safety Study Patients With Solid Tumors</brief_title>
	<detailed_description>The study conduct two part . The dose escalation portion trial subject enrol cohort increase dose level HuMax-TF-ADC 21 day treatment cycle . In Cohort Expansion part trial , explore recommend phase 2 dose HuMax-TF-ADC determine Part 1</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Patients relapse , advance and/or metastatic cancer fail available standard treatment candidate standard therapy . Patients must measurable disease Age ≥ 18 year . Acceptable renal function Acceptable liver function Acceptable hematological status ( without hematologic support Acceptable coagulation status Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Life expectancy least three month . A negative serum pregnancy test ( female age 1855 year old ) . Women pregnant breast feeding include . Patients , female male , reproductive potential must agree use adequate contraception six month last infusion HuMaxTFADC . Following receipt verbal write information study , patient must provide sign informed consent studyrelated activity carry . Known past current coagulation defect . Ongoing major bleeding , Have clinically significant cardiac disease A baseline QT interval correct Fridericia 's formula ( QTcF ) &gt; 450 msec , complete leave bundle branch block ( define QRS interval ≥ 120 msec leave bundle branch block form ) incomplete leave bundle branch block . Therapeutic anticoagulative long term antiplatelet treatment . Have receive granulocyte colony stimulate factor ( GCSF ) granulocyte/macrophage colony stimulate factor support within one week pegylated GCSF within two week Screening Visit . Have receive cumulative dose corticosteroid ≥ 100 mg ( prednisone equivalent dos corticosteroid ) within two week first infusion . No dietary supplement allow study period , except multivitamin , vitamin D calcium . Major surgery within six week open biopsy within 14 day drug infusion . Plan major surgery treatment period . Any history intracerebral arteriovenous malformation , cerebral aneurysm , brain metastasis stroke . Any anticancer therapy include ; small molecule , immunotherapy , chemotherapy monoclonal antibody experimental drug within four week five half life , whichever long , first infusion . Prior treatment bevacizumab within twelve week first infusion . Radiotherapy within 28 day prior first dose . Patients recover symptomatic side effect radiotherapy time initiation screen procedure . Known past current malignancy inclusion diagnosis , except : Cervical carcinoma Stage 1B less . Noninvasive basal cell squamous cell skin carcinoma . Noninvasive , superficial bladder cancer . Prostate cancer current PSA level &lt; 0.1 ng/mL . Any curable cancer complete response ( CR ) &gt; 5 year duration . Known human immunodeficiency virus seropositivity . Positive serology ( unless due vaccination passive immunization due Ig therapy ) hepatitis B Positive serology hepatitis C base test screening . Inflammatory bowel disease include Crohn 's disease colitis ulcerosa . Inflammatory lung disease include moderate severe asthma chronic obstructive pulmonary disease ( COPD ) require chronic medical therapy . Ongoing acute chronic inflammatory skin disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ovary cancer</keyword>
	<keyword>cervix cancer</keyword>
	<keyword>endometrium cancer</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>prostate cancer ( CRPC )</keyword>
	<keyword>esophagus cancer</keyword>
	<keyword>lung cancer ( NSCLC )</keyword>
	<keyword>Squamous cell carcinoma head neck ( SCCHN )</keyword>
</DOC>